Masimo Snags a New CEOMasimo Snags a New CEO

The new hire comes on board after an ugly proxy war that ousted longtime CEO and founder Joe Kiani.

Amanda Pedersen

January 23, 2025

2 Min Read
A close-up shot of the Masimo logo on a sign outside the company's Irvine, CA headquarters
Masimo has found a permanent CEO replacement four months after the company's founder, Joe Kiani, was ousted from the board and resigned as CEO.Image credit: Mario Tama / Getty Images

Michelle Brennan made it clear when she became Masimo's interim CEO that her top priority was to guide the company through its transition period until a permanent CEO was found and then focus on contributing to the company as a board member for the long term. Now, that duty has been fulfilled.

Irvine, CA-based Masimo has named Katie Szyman as its new CEO, and Brennan has been appointed chairman of the board. Quentin Koffey has been appointed vice chairman. The leadership shift follows an ugly proxy war between the company and Politan Capital Management that ultimately ended in the ousting of the company's founder and longtime CEO, Joe Kiani. The changes will take effect February 12.

Szyman is currently worldwide president of advanced patient monitoring at BD (Becton, Dickinson and Company). Previously, she led the critical care product group at Edwards Lifesciences, which was acquired by BD in a transaction that closed in September 2024.

“We wanted our next CEO to be someone who is passionate about the role and inspiring as well as engaging the team at Masimo, and Katie made clear that she is that person. Her advanced patient monitoring category knowledge and deep existing relationships within the industry position her to make an immediate impact as she works with the board on prioritizing our pipeline to focus on large opportunities while developing a clear strategy for bringing our next generation patient monitoring platform to market.”

Related:Career-Building Takeaways for Engineers from MD&M West 2025

While at Edwards, Szyman significantly accelerated revenue growth in the critical care product group through numerous initiatives, including entering adjacent markets through internal and external innovation and introducing the first AI technology cleared by FDA in the patient monitoring space. Masimo also noted that Szyman possesses significant operational and financial leadership experience that will aid the company as it continues to address its cost structure and improve gross margin performance.

“I have long admired Masimo as an innovation leader, and I could not be more excited about the opportunity to grow the business and deliver improved outcomes for millions more patients around the world. I believe Masimo’s leadership team and bench of talent is top-tier, and I am thrilled by the chance to work with and learn from this group.”

The company also noted that its board remains committed to the previously announced review of alternatives for both the consumer audio and consumer healthcare businesses and has engaged Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as a legal advisor.

Related:Introducing: The All-New, All-Different BD

About the Author

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like